Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.


Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
03 2023
Historique:
received: 18 08 2022
accepted: 21 11 2022
revised: 17 11 2022
pubmed: 2 12 2022
medline: 15 3 2023
entrez: 1 12 2022
Statut: ppublish

Résumé

Graft failure (GF) remains a serious issue of hematopoietic stem cell transplantation (HSCT) in inborn errors of immunity (IEI). Second HSCT is the only salvage therapy for GF. There are no uniform strategies for the second HSCTs and limited data are available on the second HSCT outcomes. 48 patients with various IEI received second allogeneic HSCT from 2013 to 2020. Different conditioning regimens were used, divided into two main groups: containing myeloablative doses of busulfan/treosulfan (n = 19) and lymphoid irradiation 2-6 Gy (n = 22). Irradiation-containing conditioning was predominantly used in suspected immune-mediated rejection of the first graft. Matched unrelated donor was used in 28 patients, mismatched related in 18, and matched related in 1. 35 patients received TCRαβ/CD19 graft depletion. The median follow-up time was 2.4 years post-HSCT. One patient died at conditioning. The OS was 0.63 (95% CI: 0.41-0.85) after busulfan/treosulfan and 0.68 (95% CI: 0.48-0.88) after irradiation-based conditioning, p = 0.66. Active infection at HSCT significantly influenced OS: 0.43 (95% CI: 0.17-0.69) versus 0.73 (95% CI: 0.58-0.88) without infection, p = 0.004. The cumulative incidence of GF was 0.15 (95% CI: 0.08-0.29). To conclude, an individualized approach is required for the second HSCT in IEI. Low-dose lymphoid irradiation in suspected immune-mediated GF may be a feasible option.

Identifiants

pubmed: 36456809
doi: 10.1038/s41409-022-01883-4
pii: 10.1038/s41409-022-01883-4
pmc: PMC10005930
doi:

Substances chimiques

treosulfan CO61ER3EPI
Busulfan G1LN9045DK

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-281

Informations de copyright

© 2022. The Author(s).

Références

Blood. 2020 Sep 3;136(10):1201-1211
pubmed: 32614953
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
Int J Radiat Oncol Biol Phys. 2021 Mar 17;:
pubmed: 33810948
Front Pediatr. 2019 Aug 08;7:295
pubmed: 31440487
Bone Marrow Transplant. 2013 Apr;48(4):537-43
pubmed: 23222384
Br J Haematol. 2000 Oct;111(1):292-302
pubmed: 11091216
Bone Marrow Transplant. 2018 May;53(5):521-534
pubmed: 29335625
Drugs. 2018 Jul;78(11):1085-1103
pubmed: 29961185
Pediatr Blood Cancer. 2011 Feb;56(2):289-93
pubmed: 21157896
Blood. 2011 Aug 11;118(6):1675-84
pubmed: 21659547
Bone Marrow Transplant. 2015 Oct;50(10):1312-5
pubmed: 26121106
Blood. 2022 Mar 31;139(13):2066-2079
pubmed: 35100336
Biol Blood Marrow Transplant. 2018 Jul;24(7):1432-1440
pubmed: 29550630
Clin Transplant. 2011 Jan-Feb;25(1):E68-76
pubmed: 20946467
J Allergy Clin Immunol. 2013 Apr;131(4):994-1000
pubmed: 23465660
Biol Blood Marrow Transplant. 2020 Oct;26(10):1923-1929
pubmed: 32653621
J Allergy Clin Immunol. 2015 Apr;135(4):988-997.e6
pubmed: 25595268
Semin Radiat Oncol. 2010 Jan;20(1):12-20
pubmed: 19959027
J Clin Immunol. 2017 Aug;37(6):548-558
pubmed: 28752258
Blood. 2019 Nov 14;134(20):1755-1763
pubmed: 31558465
Blood. 2015 Oct 15;126(16):1885-92; quiz 1970
pubmed: 26185129
Bone Marrow Transplant. 2020 Sep;55(9):1796-1809
pubmed: 32203264
Front Pediatr. 2019 Nov 06;7:434
pubmed: 31781522
Bone Marrow Transplant. 2021 Sep;56(9):2052-2062
pubmed: 34226669
J Allergy Clin Immunol. 2018 Apr;141(4):1417-1426.e1
pubmed: 28780238
Blood. 2014 Jul 31;124(5):822-6
pubmed: 24869942
J Allergy Clin Immunol. 2018 Jan;141(1):322-328.e10
pubmed: 28392333
Biol Blood Marrow Transplant. 2020 Jul;26(7):1332-1341
pubmed: 32234377
Blood. 2016 Jun 23;127(25):3281-90
pubmed: 27099148
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):137-143
pubmed: 30593907
Strahlenther Onkol. 2013 Jul;189(7):529-34
pubmed: 23703403
Biol Blood Marrow Transplant. 2017 Mar;23(3):483-490
pubmed: 28039080

Auteurs

Alexandra Laberko (A)

Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. alexandra.laberko@gmail.com.
Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK. alexandra.laberko@gmail.com.

Elvira Sultanova (E)

Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Aishat Idarmacheva (A)

Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Yulia Skvortsova (Y)

Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Larisa Shelikhova (L)

Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Alexei Nechesnyuk (A)

Department of Radiation Therapy, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Daria Kobyzeva (D)

Department of Radiation Therapy, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Anna Shcherbina (A)

Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Michael Maschan (M)

Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Alexei Maschan (A)

Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Dmitry Balashov (D)

Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH